Skip to content

The impact andmechanism of recombinant human luteinizing hormone supplementation on IVF outcomes at and after trigger day: a prospective randomised, open-label study

The impact of recombinant human luteinizing hormone supplementation on IVF outcomes after trigger day: a prospective randomised, open-label study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16008385
Enrollment
Unknown
Registered
2016-04-28
Start date
2016-04-30
Completion date
Unknown
Last updated
2017-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

Intervention Group:Conventional luteal support+ r-hLH

Sponsors

General Hospital of Ningxia Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 42 Years

Inclusion criteria

Inclusion criteria: 1. According to the WHO standards, the diagnosis of infertility (primary or secondary); 2. women who have indications for IVF or ICSI; 3. Age younger than 42 years; 4. Women with BMI <28 kg /m2; 5. Women undergoing their first cycle of IVF or ICSI or nearly three months ago; 6. Serum LH level <1.2 mIU/L on trigger day; 7. HCG trigger; 8. Women who signed the informed consent; 9. Patient with fresh embryo transfer; 10. HCG, GnRHa cant be used for luteal support;

Exclusion criteria

Exclusion criteria: 1. Abnormal uterine cavity caused by serious uterine malformation or abnormality,adenomyosis, myoma or intrauterine adhesions detected by ultrasound or hysteroscopy were excluded; 2. women with serious hydrosalpinx affecting uterine cavity by ultrasound were excluded; 3. Women can not receive ART treatment or pregnancy and untreated or uncontrolled disease such as poorly controlled Type I or Type II diabetes; liver disease or dysfunction (based on serum liver enzyme testing);thyriod or renal disease or abnormal serum thyriod or renal function; hyperprolactinemia, significant anemia; history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident; uncontrolled hypertension, known symptomatic heart disease; history of or suspected cervical, endometrial or breast carcinoma and atypical hyperplasia ; undiagnosed vaginal bleeding were excluded; 4. experienced recurrent spontaneous abortion with immune causes were excluded ; 5. ICSI with fresh sperm with white blood cell or testicular spermatozoa with nonobstructive azoospermia on oocyte pick-up day; 6. couples with female or male abnormal karyotype including chromosome polymorphism; 7. women who is allergic to r-hLH; 8. couples (female or male) with long heavy smooking history (10 cigarettes per day for 1 year); 9. IVF cycle by egg donor; 10. Women who are unable to comply with the study procedures.

Design outcomes

Primary

MeasureTime frame
clinical pregnancy rate (PR);

Secondary

MeasureTime frame
live birth rate;incidence of OHSS;Embryo implantation rate;miscarriage rate;duration of luteal support;

Countries

China

Contacts

Public ContactZhao Junli

General Hospital of Ningxia Medical University

zhaojunli6812@163.com+86 13909519609

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026